Key Takeaways
- Revenue surged, but the base effect is real: Consolidated revenue grew 35.2% YoY in Q3 and 157% in 9M, though the 9M figure is inflated by the Ratnatris acquisition contributing only 17 days in the prior-year period.
- CDMO is the story, and Q4 is the inflection: The CDMO segment grew 68% YoY, and management expects its share of regulated revenue to rise significantly QoQ as 15-17 new CDMO products commercialize in Q4.
- Regulated market margins are the profit engine: The regulated segment delivered ~40% EBITDA margins, driven by own products and CDMO, while emerging markets remained at ~1% as the business model transition is still underway.
- Next year’s guide is aggressive: Management expects FY26 revenue of INR 670-700 crores (vs. ~INR 410-440 crores in FY25), implying 50-60%+ growth, with PAT nearly doubling.
- What to watch next quarter: Whether the 15-17 CDMO launches actually materialize in Q4, the pace of emerging market margin improvement toward high single digits, and any update on the injectables CAPEX timeline.
CDMO & Regulated Market Growth
- CDMO revenue cycle beginning: The CDMO segment grew 68% YoY, and management described Q3 as just the start of the cycle, with a strong tailwind expected to capture growth aggressively from Q4 onward.
- 15-17 launches in Q4: Out of a 69-product pipeline, 15-17 CDMO/CMO products are expected to commercialize in Q4 FY25, on top of the 21 products already live.
- Full-year exposure coming: The 21 currently commercialized products will give complete three-month and full-year exposure in FY26, providing a base for sustained growth.
- US plant is a narrow-moat asset: Only 4-5 players offer similar controlled-substance and government-focused manufacturing capability from a US-based site, limiting competitive pressure and price erosion.
- No para IV exposure: The company operates only in generics, not para IV, so the aggressive price erosion typical of first-to-file challenges does not apply to its portfolio.
- End-to-end CDMO proposition: The company offers R&D through regulatory support to commercial manufacturing, and with the API facility coming online, it will cover intermediates through finished goods distribution, a combination management claims few peers of similar size can match.
Swapnil Shah: "I personally don't know in our size any company has that kind of capability to offer to our CDMO partners. So, I think that mixture is unique, that mixture is different and that will continue to leverage upon it."
Emerging Markets Turnaround
- Revenue growth distorted by acquisition math: Emerging market revenue grew 289% YoY in Q3 and more than 10x in 9M, but Ratnatris was acquired on December 14, 2023, so the prior-year quarter included only 17 days of revenue.
- Margins are near zero for now: Emerging market EBITDA was 1% in Q3 and 1.4% in 9M, reflecting a legacy focus on lower-margin African markets and an ongoing pivot to CIS, Southeast Asia, and Latin America.
- Business model shift underway: The company is transitioning from a P2P model to a distributor/CDMO model based on product registrations; 237 products are already registered, but it takes 9-12 months post-registration to tie up with partners and start marketing.
- Profit-share model drives future margin: Revenue is recognized as a profit share from marketing partners, meaning the gross revenue line carries no cost of goods below it, which should produce a structurally better margin profile as the model scales.
- Margin target set: Management’s internal target at optimum level is at least 15-18% EBITDA, with next year expected to reach high single digits and higher teens targeted by FY26-27 or FY27-28.
- New greenfield site planned: The company is scouting for a greenfield site in India to cater to mid-tier emerging markets, with the process started immediately.
Sanjay Majmudar: "I think it's a little premature, but as Swapnil explained, when we acquired this business and then we have started transforming it, I think an optimum targeted level of EBITDA would be much higher, but we will speak as we go forward. But our internal target at the optimum level is at least 15% to 18%."
Margin Structure & Profitability
- Consolidated margin expansion: EBITDA margin rose 810 bps YoY to 27% in Q3 and 870 bps to 26% in 9M, reflecting operating leverage as revenue scaled.
- Regulated market is the profit center: The regulated segment delivered ~40% EBITDA margins in both Q3 and YTD, driven by own products (higher margin than CDMO) and CDMO.
- CDMO margin undisclosed: Management declined to break out CDMO-specific margins, directing analysts to the consolidated regulated market figure of ~40% as the relevant benchmark.
- Own products carry premium margins: Within the regulated segment, own products earn higher margins than CDMO, and products that enjoyed a Competitive Generic Therapy (CGT) window earned higher still, though that window has now closed for existing products.
- Product-level diversification protects margin: No single product contributes more than 2-3% of revenue, so even if one product faces heavy competition, the overall revenue impact is only about 1%.
Swapnil Shah: "Our dependency on each product revenue stream is not more than 2% to 3%. So, even if that one product can give me a lot of competition, my revenue drops from 3% to 1.5% or maybe 2%. In overall scheme of things you look at it, my revenue is dropped only 1% from a competition..."
Product Portfolio & Competitive Position
- Niche, underpenetrated product philosophy: The company targets products that large pharma companies want in their pipeline but are not interested in developing themselves, positioning Senores as a partner rather than a competitor.
- Portfolio maturity in phases: Of the 27-28 own products, 30-35% will reach optimum market share in the next 6-12 months, another 30-35% have either reached or will soon reach optimum, and the remaining 30-35 products are at a stable level with no major expected change.
- CDMO customer base broadening: The top two CDMO customers account for 10-12 products, while another 2-3 customers each have 1-3 products, and none of these products have yet reached optimal levels.
- US manufacturing as a moat: Being a US-based manufacturer for controlled substances and government business means the company competes with local US manufacturers, not foreign sites, limiting the competitive field to 4-5 players with similar capability.
- FDA track record clean: The most recent FDA audit was approved without any observation, and regular customer audits by large global pharma companies help ensure continuous cGMP compliance.
Sanjay Majmudar: "We generally identify products which are relatively niche, underpenetrated. We have a very different philosophy. And then these are the products we generally large, big pharmas are not interested. But since they want it as a part of their pipeline, that is when we fit in very nicely. We don't compete with them. Rather, they are all our partners."
Capacity Expansion & Backward Integration
- API facility imminent: The greenfield API facility at Chhatral is likely to commence soon, with the regulated market facility expected to start this quarter, enabling backward integration of key products.
- In-house API supply timeline: A good portion of current API supply will come from in-house manufacturing after about a year, and the company intends for the API site to be approved or approvable by all regulatory authorities including the USFDA.
- Injectables CAPEX starting Q1: Groundwork for the injectables facility has begun, with actual CAPEX spending to start from Q1 of next year and completion expected within 18-24 months; the site will be at the existing oral solid dosage location, leveraging existing land, labs, and infrastructure.
- US plant utilization rising: Utilization at the US facility is expected to inch up to 60-65% in FY26 as new product launches ramp.
- Single-plant risk acknowledged: When asked about de-risking USFDA single-plant exposure, management said it has thoughts around it and will look into it, but offered no specific plan or timeline.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| CDMO product launches | 15-17 CDMO/CMO products to commercialize | Q4 FY25 |
| FY25 revenue | INR 410-440 crores (+/-5%) | FY25 full year |
| FY26 revenue | INR 670-700 crores (50-60%+ growth) | FY26 full year |
| FY26 PAT | Nearly double vs. FY25 | FY26 full year |
| Emerging market EBITDA | Improve to high single digits | FY26 |
| Emerging market EBITDA | Reach higher teens | FY26-27 to FY27-28 |
| US plant utilization | Inch up to 60-65% | FY26 |
| API facility commencement | Regulated market API facility to start | Current quarter (Q4 FY25) |
| Injectables CAPEX | CAPEX spending to begin; completion in 18-24 months | Starting Q1 FY26 |
| Product launches | 5 products to launch | Q4 FY25 |
Key Metrics
| Metric | Q3 FY25 |
|---|---|
| Consolidated revenue | ₹906 cr, +35.2% YoY |
| 9M FY25 consolidated revenue | ₹288 cr, +157% YoY from ₹112 cr in 9M FY24 |
| Regulated markets revenue | ₹70 cr, +3% YoY |
| CDMO business growth | 68% YoY |
| Emerging markets revenue | ₹26 cr, +289% YoY; Q3 FY24 included Ratnatris for only 17 days post-acquisition |
| 9M FY25 revenue mix | 64% regulated markets, 30% emerging markets, balance API and injectables |
| EBITDA | ₹29 cr, +92% YoY from ₹15 cr in Q3 FY24 |
| EBITDA margin | 27%, up from 19% in Q3 FY24, an increase of ~810 bps |
| Regulated business EBITDA margin | ~40% in Q3 and YTD |
| Emerging markets EBITDA margin | 1% in Q3, 1.4% in 9M FY25 |
| PAT after minority interest | ₹17 cr, +142% YoY from ₹7 cr in Q3 FY24 |
| PAT margin | 16%, up from 9% in Q3 FY24, an increase of 710 bps |
| CDMO revenue as % of total revenue | ~11% in Q3, ~12-13% YTD |
| CDMO as % of regulated markets revenue | ~19% in Q3, ~24% in 9M FY25 |
| Own products commercialized in regulated markets | 22 products; 5 more expected to launch in Q4 FY25 |
| Approved ANDAs | 24 as of call date; 5 new approvals received in the quarter |
| Pipeline products (regulated markets) | 51 products; 28 have CGT opportunity |
| CDMO/CMO commercial products | 21 products; 69 in pipeline; 15-17 expected to commercialize in Q4 FY25 |
| Emerging markets registered products | 267 products; 62 added in the quarter |
| Emerging markets products under registration | 537 products; 131 new filings planned |
| US plant utilization | ~50% currently; capacity augmented ~5x vs DRHP; expected to reach 60-65% in FY26 |
| India plant utilization | ~60-65%, possibly 65-70% |
| FY25 full-year revenue expectation | ₹410 cr to ₹440 cr (+/-5%) |
| FY26 revenue expectation | ₹670 cr to ₹700 cr |
| FY26 CDMO/CMO revenue expectation | $25 mn to $30 mn |
| FY25 full-year PAT expectation | ₹55 cr to ₹60 cr |
| FY26 CAPEX | More than ₹200 cr firmly on the ground |
| Top 5 customers share of own-product revenue | ~65% |
| Revenue dependency per own-product | Not more than 2% to 3% per product |